Batlivala & Karani

| VISII UPDAIE | | | | | | | |
|----------------------|------------|-----|--------|--|--|--|--|
| Large Cap | | | | | | | |
| Share Data | | | | | | | |
| Reuters code | |] | ITC.BO | | | | |
| Bloomberg code | | | ITC IN | | | | |
| Market cap. (US\$ m | 28,580 | | | | | | |
| 6M avg. daily turnov | 26.5 | | | | | | |
| Issued shares (mn) | | | 7,699 | | | | |
| Target price (Rs) | | | 180 | | | | |
| Performance (%) | 1 M | 3M | 12M | | | | |
| Absolute | (5) | (4) | 39 | | | | |

Valuation ratios

Relative


| FY11E | FY12E |
|-------|--|
| 6.4 | 7.4 |
| 19.8 | 16.1 |
| 26.3 | 22.6 |
| 7.6 | 6.6 |
| 1.6 | 1.9 |
| 5.9 | 5.1 |
| 17.0 | 14.7 |
| | 6.4 19.8 26.3 7.6 1.6 5.9 |

(5)

(5)

| FIIs | 14 |
|-----------------|----|
| MFs | 14 |
| BFSI's | 22 |
| Public & Others | 50 |

Relative performance



ITC

16

Price: Rs 167

BSE Index: 20,016

Maintain Outperformer

23 December 2010

Growth momentum intact

We met the management of ITC. Following are the key takeaways:

Cigarettes – On a strong footing

- The company expects positive volume growth in 2HFY11 led by recovery in the regular segment (Rs 2-3.5 price point). Cigarette volumes had dipped in 1HFY11 due to the steep 15% increase in excise duties. The company expects flat volume growth for FY11, in line with our assumptions.
- Competition from the launch of Marlboro's regular variant (Rs 3.5 price point) has not had a significant impact and the company is closely monitoring the progress of the brand. ITC launched 'Lucky Strike' in the kings segment (Rs 5.5 price point) in July and 'Players Gold Leaf' (Rs 3 price point) in October in a bid to increase presence at these price points. Launches at the Rs 1.5 price point (micro filter) have seen limited traction. This is due to the presence of unorganised and illegal competition at Re 1 price point that has grown significantly and now constitutes $\sim 8\%$ of industry volumes.
- The benefit of lower leaf tobacco prices (10-15% decline in the past three months) is expected to accrue only in FY12 because ITC maintains high tobacco inventory of ~15 months. The company believes that with improving product mix and staggered pricing increases, ~30 bps margin expansion in FY12 is sustainable.

FMCG - Strong growth momentum, losses continue to decline

- Profitability in foods has improved driven by higher margins in biscuits and staples, which has been a key factor in narrowing FMCG losses in FY11 until now. With the exception of Bingo and the recently launched noodles, the foods portfolio has been positively contributing to the division's PBIT. The company expects the FMCG division to break even at the PBIT level by FY13. Personal care, however, would take four-five years to achieve break even.
- In personal care, ITC has maintained market share at 5% in soaps and 3-3.5% in shampoos. The company has identified skin care as a major opportunity. Apart from fairness creams, it would be looking at further launches in this space.
- The company is satisfied with its launches in the noodles and fairness cream space and will be rolling out brands across markets over the next three months.

Hotels - Expect gradual improvement

- Average Room Rate (ARR) growth has been moderate with the key Delhi and Mumbai markets seeing an increase in supply. The company expects a gradual improvement in ARRs over the next seven-eight quarters as demand picks up to match supply in these markets.
- The 600-room Chennai property will be launched in 1QFY12. ITC is also planning a 100-room property in Gurgaon, a 500-room property in Kolkata, and a 120-room property in Bangalore, which would be ready for launch by FY15-16.



Other key highlights


- In 1HFY11, **paper** margins improved largely due to an improving mix (higher sales of value added paperboards). The company expects to maintain revenue growth momentum with sustainable PBIT margins of 21-22%. However, since it is operating at optimum capacity utilisation levels, paper margins could positively surprise in the next two-three quarters. To service increased paperboard demand, the company will be adding a 100,000 tonnes paperboard machine by end-FY12 at a capex of Rs 6-7 bn.
- In the **agri** division, although leaf tobacco prices have corrected 10-15%, export realisations have remained firm. Hence we do not expect a significant correction in agri margins. The company expects to maintain PBIT margins at 10-11% and would focus on higher margin exports of leaf tobacco and soya.
- The company has reduced its stake in Agrotech Foods and VST Industries and is looking to exit these investments completely in the near future.

Outlook and valuation

ITC's cigarette business continues to display resilience with volumes recovering within six months following the steep 15% price increase. Providing for a moderate 5-6% increase in excise duties in the forthcoming budget, we expect cigarette volumes to grow 5%+ in FY12. Cigarette margins have continued to surprise on the upside; given a reducing input cost scenario, we expect further margin expansion, which would drive profitability in FY12. The FMCG division continues to record 20%+ growth and the company expects it to break even in FY13. Thus, losses could be much lower in FY12 versus our assumption of 35% decline. An improving volume growth outlook for cigarettes and improving profitability across divisions (except agri) are expected to drive the strong 18% earnings CAGR over FY10-12. This engenders reasonable valuations of 22.6x FY12 earnings for ITC (average FY12 P/E for our FMCG coverage universe is ~24x). We are positive on ITC and maintain our **Outperformer** rating on the stock.

| Value of division | Rs/share | Notes |
|--|----------|--|
| Cigarettes (A) | 140.0 | Based on DCF valuation |
| FMCG | 10.8 | 2x FY12E sales to categories that have broken even, 1x FY12E to |
| Hotels | 7.6 | the other categories |
| Paper & Paperboards | 9.6 | 5x FY12E EBITDA |
| Agribusiness | 4.2 | 6x FY12E EBITDA |
| Cash and investment in subsidiaries | 8.1 | At current valuations |
| Total of the non-cigarettes business divisions (B) | 40.3 | |
| Total (A+B) | 180.3 | |

| S | 0 | Т | р | val | lua | tio | n |
|---|---|---|---|-----|-----|-----|---|
| | | | | | | | |



Source: B&K Research

B&K RESEARCH

| Income Statement | | | | | |
|--|-----------|-----------|-----------|-----------|--|
| Yr end 31 Mar (Rs mn) FY09 FY10 FY11E FY11 | | | | | |
| Net sales | 156,119 | 181,532 | 210,471 | 240,961 | |
| Growth (%) | 11.9 | 16.3 | 15.9 | 14.5 | |
| Operating expenses | (107,082) | (120,315) | (137,952) | (157,073) | |
| Operating profit | 49,037 | 61,217 | 72,519 | 83,888 | |
| EBITDA | 49,037 | 61,217 | 72,519 | 83,888 | |
| Growth (%) | 10.9 | 24.8 | 18.5 | 15.7 | |
| Depreciation | (5, 494) | (6,087) | (6, 444) | (6,938) | |
| Other income | 4,897 | 5,556 | 6,124 | 6,852 | |
| EBIT | 48,441 | 60,687 | 72,198 | 83,802 | |
| Interest paid | (183) | (534) | (283) | (285) | |
| Pre-tax profit | 48,257 | 60,153 | 71,916 | 83,517 | |
| (before non-recurring) | | | | | |
| Pre-tax profit (after non-recurring) | 48,257 | 60,153 | 71,916 | 83,517 | |
| Tax (current + deferred) | (15,651) | (19,654) | (23,013) | (26,726) | |
| Net profit (before Minori Interest, Pref. Dividend, | • | 40,499 | 48,903 | 56,792 | |
| Prior period adjustments | 30 | 111 | 0 | 0 | |
| Reported PAT | 32,636 | 40,610 | 48,903 | 56,792 | |
| Adjusted net profit | 32,636 | 40,610 | 48,903 | 56,792 | |
| Growth (%) | 4.6 | 24.4 | 20.4 | 16.1 | |

| Balance Sheet | | | | |
|-----------------------------|----------------|---------|---------|---------|
| Yr end 31 Mar (Rs mn | h) FY09 | FY10 | FY11E | FY12E |
| Cash and marketable sec. | 29,765 | 54,963 | 52,783 | 73,905 |
| Other current assets | 71,287 | 70,008 | 79,016 | 88,740 |
| Investments | 8,923 | 13,569 | 13,569 | 13,569 |
| Net fixed assets | 84,860 | 91,514 | 99,219 | 106,594 |
| Total assets | 194,835 | 230,053 | 244,586 | 282,808 |
| | | | | |
| Current liabilities | 47,036 | 80,482 | 66,941 | 77,365 |
| Total debt | 1,776 | 1,077 | 1,009 | 1,110 |
| Other non-current liabiliti | ies 8,672 | 7,850 | 7,850 | 7,850 |
| Total liabilities | 57,484 | 89,410 | 75,799 | 86,325 |
| | | | | |
| Share capital | 3,774 | 3,818 | 7,677 | 7,677 |
| Reserves & surplus | 133,576 | 136,826 | 161,109 | 188,805 |
| Shareholders' funds | 137,351 | 140,644 | 168,786 | 196,483 |
| Total equity & liab. | 194,835 | 230,053 | 244,586 | 282,808 |
| Capital employed | 147,798 | 149,571 | 177,645 | 205,443 |

| Yr end 31 Mar (Rs mn |) FY09 | FY10 | FY11E | FY12E |
|----------------------------|---------------|-----------|-----------|-----------|
| Pre-tax profit | 48,257 | 60,153 | 71,916 | 83,517 |
| Depreciation | 5,494 | 6,087 | 6,444 | 6,938 |
| Change in working capital | (4,977) | 6,541 | (2, 646) | (3,776) |
| Total tax paid | (12, 444) | (20, 476) | (23,013) | (26, 726) |
| Other operating activities | 30 | 111 | 0 | 0 |
| Cash flow from oper. (a) | 36,361 | 52,416 | 52,701 | 59,954 |
| Capital expenditure | (16,862) | (12,041) | (14,150) | (14, 313) |
| Change in investments | 968 | (28, 891) | 0 | 0 |
| Others | (535) | (700) | 0 | 0 |
| Cash flow from inve. (b) | (16,429) | (41,633) | (14,150) | (14,313) |
| Free cash flow (a+b) | 19,931 | 10,784 | 38,552 | 45,641 |
| Equity raised/(repaid) | 448 | 7,207 | 3,859 | 0 |
| Debt raised/(repaid) | (369) | (698) | (68) | 101 |
| Dividend (incl. tax) | (15, 432) | (16,339) | (44, 523) | (24, 619) |
| Others | 30 | (1) | 0 | 0 |
| Cash flow from fin. (c) (| 15,324) | (9,831) | (40,732) | (24,518) |
| Net chg in cash (a+b+c) | 4,608 | 953 | (2,180) | 21,123 |

Cash Flow Statement


| Key Ratios | | | | |
|-----------------------|--------|--------|--------|--------|
| Yr end 31 Mar (%) | FY09 | FY10 | FY11E | FY12E |
| Adjusted EPS (Rs) | 4.3 | 5.3 | 6.4 | 7.4 |
| Growth | 4.4 | 23.0 | 19.8 | 16.1 |
| Book NAV/share (Rs) | 18.1 | 18.3 | 21.9 | 25.5 |
| Dividend/share (Rs) | 1.9 | 5.0 | 2.8 | 3.3 |
| Dividend payout ratio | 50.1 | 109.6 | 50.3 | 51.2 |
| Tax | 32.4 | 32.7 | 32.0 | 32.0 |
| EBITDA margin | 31.4 | 33.7 | 34.5 | 34.8 |
| EBIT margin | 31.0 | 33.4 | 34.3 | 34.8 |
| RoCE | 35.1 | 40.8 | 44.1 | 43.8 |
| Net debt/Equity | (20.4) | (38.3) | (30.7) | (37.0) |

| Valuations | | | | | |
|-------------------|------|------|-------|-------|--|
| Yr end 31 Mar (x) | FY09 | FY10 | FY11E | FY12E | |
| PER | 38.7 | 31.5 | 26.3 | 22.6 | |
| PCE | 33.1 | 27.4 | 23.2 | 20.2 | |
| Price/Book | 9.2 | 9.1 | 7.6 | 6.6 | |
| Yield (%) | 1.1 | 3.0 | 1.6 | 1.9 | |
| EV/Net sales | 7.9 | 6.8 | 5.9 | 5.1 | |
| EV/EBITDA | 25.2 | 20.2 | 17.0 | 14.7 | |

| Du Pont Analysis – ROE | | | | | | |
|------------------------|------|------|-------|-------|--|--|
| Yr end 31 Mar (x) | FY09 | FY10 | FY11E | FY12E | | |
| Net margin (%) | 20.9 | 22.4 | 23.2 | 23.6 | | |
| Asset turnover | 0.9 | 0.9 | 0.9 | 0.9 | | |
| Leverage factor | 1.4 | 1.5 | 1.5 | 1.4 | | |
| Return on equity (%) | 25.3 | 29.2 | 31.6 | 31.1 | | |

Harit Kapoor harit.kapoor@bksec.com +91-22-4031 7130 Ashit Desai ashit.desai@bksec.com +91-22-4031 7132

Analyst Declaration: We, Harit Kapoor & Ashit Desai, hereby certify that the views expressed in this report accurately reflect our personal views about the subject securities and issuers. We also certify that no part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendation or view expressed in this report.



B&K Securities is the trading name of Batlivala & Karani Securities India Pvt. Ltd.

B&K Investment Ratings:

1. **BUY:** Potential upside of > +25% (absolute returns)

0 to +25%

- 2. OUTPERFORMER:
- 3. UNDERPERFORMER: 0 to -25%
- 4. **SELL:** Potential downside of < -25% (absolute returns)

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, print, publishing, photocopying, recording or otherwise without the permission of Batlivala & Karani Securities India Pvt. Ltd. Any unauthorized act in relation to all or any part of the material in this publication may call for appropriate statutory proceedings.

The information contained herein is confidential and is intended solely for the addressec(s). Any unauthorized access, use, reproduction, disclosure or dissemination is prohibited. This information does not constitute or form part of and should not be construed as, any offer for sale or subscription of or any invitation to offer to buy or subscribe for any securities. The information and opinions on which this communication is based have been complied or arrived at from sources believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to their accuracy, correctness and are subject to change without notice. Batlivala & Karani Securities India P Ltd and/ or its clients may have positions in or options on the securities mentioned in this report or any related investments, may effect transactions or may buy, sell or offer to buy or sell such securities or any related investments. Recipient/s should consider this report only for secondary market investments and as only a single factor in making their investment decision. The information enclosed in the report has not been vetted by the compliance department due to the time sensitivity of the information/document. Some investments discussed in this report have a high level of volatility. High volatility investments may experience sudden and large falls in their value causing losses when the investment is realized. Those losses may equal your original investment. Some investments may not be readily realizable and it may be difficult to sell or realize those investments, similarly it may prove difficult for you to obtain reliable information about the value, risks to which such an investment is exposed. Neither B&K Securities nor any of its affiliates shall assume any legal liability or responsibility for any incorrect, misleading or altered information contained herein.

B & K SECURITIES INDIA PRIVATE LTD.

Equity Research Division: City Ice Bldg, 298, Ground/1st Floor, Perin Nariman Street, Behind RBI, Fort, Mumbai - 400 001, India. Tel.: 91-22-4031 7000, Fax: 91-22-2263 5020/30. Registered Office: Room No. 3/4, 7 Lyons Range, Kolkata - 700 001. Tel.: 91-33-2243 7902.

B&K Research is also available on Bloomberg <BNKI>, Thomson First Call & Investext.